Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum
Rhea-AI Summary
Longeveron (NASDAQ: LGVN) announced that its Chief Science Officer Dr. Joshua Hare and Chief Medical Officer Dr. Nataliya Agafonova will speak at the Global CardioVascular Clinical Trialists (CVCT) Forum in Washington, D.C., December 8-10, 2025.
The executives will join multiple panel discussions on cell therapy for heart failure, including delivery routes, cell types (mesenchymal stem cell therapy for dilated cardiomyopathy referencing POSEIDON and PATH AHEAD), and multi‑stakeholder debate on streamlining cell therapy innovation while maintaining evidence standards.
Positive
- None.
Negative
- None.
MIAMI, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that its Chief Science Officer, Dr. Joshua Hare, and Chief Medical Officer, Dr. Nataliya Agafonova, will speak on multiple panel discussions at the Global CardioVascular Clinical Trialists (CVCT) Forum taking place December 8-10, 2025 in Washington, D.C. The CVCT Forum seeks to promote rigorous evidence generation and accelerate the global impact of cardiovascular clinical trials.
Panel Discussions – December 8, 2025
Cell Therapy Heart Failure Trials – Cells Deliver and Disease Specific Strategies
Is Cell Delivery Route Important?
Intravenous Delivery of Cells/Cell Products: The Magic Bullet? Dr. Joshua Hare
What Type of Cells?
Mesenchymal Stem Cell Therapy for Dilated Cardiomyopathy: Lessons from POSEIDON and the PATH AHEAD – Dr. Joshua Hare
How to Streamline Cell Therapy Innovation, Not Compromising the Level of Evidence
The CVCT Multi-Stakeholder Think Tank Debate
Dr. Nataliya Agafonova, Panelist
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (Lomecel-B®), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Pediatric Dilated Cardiomyopathy (DCM). Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.
Investor and Media Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com
Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/e9e96d9c-d6c3-4aec-ba85-36631b520211
https://www.globenewswire.com/NewsRoom/AttachmentNg/f106bde7-972a-4687-a91e-03e924f409fc
FAQ
When will Longeveron executives speak at the CVCT Forum (LGVN)?
Which Longeveron (LGVN) executives are presenting at the December 2025 CVCT Forum?
What topics will Longeveron (LGVN) cover at the CVCT Forum panels on December 8, 2025?
Will Longeveron (LGVN) discuss results from POSEIDON and PATH AHEAD at the CVCT Forum?
How can investors learn more about Longeveron (LGVN) presentations at the CVCT Forum?
Does Longeveron (LGVN) participation at CVCT Forum indicate new clinical data releases?
